SCHEMBL3841685

SCHEMBL3841685

CC(C)(C)OC(=O)N1CCC(O)C(CNC(=O)OCc2ccccc2)C1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.49
KDM4E B2RXH2 1/20 0.49
PKM P14618 1/20 0.49
HTT P42858 1/20 0.48
JAK2 O60674 1/20 0.47
JAK1 P23458 1/20 0.47
STS P08842 1/20 0.47
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
ABCB1 P08183 1/20 0.45
SYK P43405 1/20 0.44
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
CTSK P43235 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HSD11B1 P28845 1/20 0.43
YAP1 P46937 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3839319 0.93 GPR119 (0.50) GPR119KDM4EPKMHTTJAK2
SCHEMBL25684610 0.93 GPR119 (0.50) GPR119KDM4EPKMHTTJAK2
SCHEMBL29716686 0.93 GPR119 (0.50) GPR119KDM4EPKMHTTJAK2
SCHEMBL18264040 0.92 NAMPT (0.47) GPR119KDM4EPKMHTTSTS
SCHEMBL3272843 0.92 NAMPT (0.47) GPR119KDM4EPKMHTTSTS
SCHEMBL3274653 0.92 NAMPT (0.47) GPR119KDM4EPKMHTTSTS
SCHEMBL3107581 0.92 NAMPT (0.47) GPR119KDM4EPKMHTTSTS
SCHEMBL3273815 0.92 NAMPT (0.47) GPR119KDM4EPKMHTTSTS
SCHEMBL12723099 0.87 KDM4E (0.60) GPR119KDM4EPKMHTTJAK2
SCHEMBL3272146 0.87 KDM4E (0.60) GPR119KDM4EPKMHTTJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071592-B2 Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones GLAXO GROUP LIMITED (GB) 2011-12-06 US disclosed
US-20090270374-A1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
EP-2044077-A1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES Glaxo Group Limited (GB) 2009-04-08 EP disclosed
EP-1992628-A1 Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones GLAXO GROUP LIMITED (GB) 2008-11-19 EP disclosed
WO-2008009700-A1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES GLAXO GROUP LIMITED (GB) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270374-A1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES ETFA, NQO2, GNAQ GPR119 4467/4885KDM4E 2078/4885PKM 3619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.